Alamar Biosciences, Inc. (ALMR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$30.80+0.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ALMR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
No current thesis-health read is available for this company.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -3.8% |
| Our one-year growth estimate | diamond | Not available |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ALMR — director transition
Dated 2026-09-01
Director — Robert Ragusa: The filing discloses the appointment of a new director to the board and its committees, which is a standard governance event and not an executive departure.
Why it matters: A strong Q3 report would show the earnings beat was not a one-time event. It could boost investor confidence.
Supportive ifQ3 earnings report shows revenue growth above 10% year over year.
Worry ifQ3 earnings report shows revenue growth below 5% year over year.
Why it matters: If health care sector growth speeds up, it could benefit Alamar's performance.
Supportive ifHealth care sector revenue growth accelerates back toward 12% year over year.
Worry ifHealth care sector revenue growth continues to decelerate below 6% year over year.
Why it matters: New board members can change company strategy and rules. This can affect future results.
Watch forNew director's plans lead to a strategy change that improves company results.
Also watch forNo clear changes in strategy or results after the new director starts.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$302 on $10,000 · ±3.0% | How much price usually moves either way. |
| Bad day | $679 loss on $10,000 · 6.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,848 loss on $10,000 · 28.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.